About us

ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens.


Vision & Mission

Toward a new paradigm of cold tumor treatment

ErVimmune develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies to address a high medical need in cold tumors.

We are dedicated to discovering more accurate tumor epitopes that are shared between patients. We focus on non-conventional cancer epitopes derived from endogenous retroviruses (HERVs). Our approach is based on new bioinformatics algorithms to identify potential epitopes that are validated by proteomics and immunology assays: from bioinformatics to proteomics.


A biotechnology company
at a preclinical stage

Founded in October 2019 by Prof. Stéphane Depil, financially supported by BPIFrance and a life science investor Seventure (seed investment of 2.5 M€).

Fully integrated in a cutting-edge cancer center and connected to the academic lab “Development of immunotherapies targeting non-conventional tumor antigens” directed by Prof. Stéphane Depil @Cancer Research Center of Lyon (CRCL)/Centre Léon Bérard, with a high-calibre team of experts.

Company management

ErVimmune Team 

“ ErVimmune develops cancer vaccines and T cell-based immunotherapies targeting new tumor antigens to address a high medical need in cold tumors. The first candidates are represented by virus-like antigens derived from Human Endogenous Retroviruses (HERVs)”

Stéphane Depil

Stéphane Depil

MD, PhD – Founder, Chairman

Nathalie Donne


Yann Estornes

PhD – Director of preclinical operations

Philip Parkinson


Paola Bonaventura

PhD – Project leader vaccine programs

Nicolas Chuvin

PhD – Project leader engineered T cells programs

Felix Raimundo

PhD – Senior computational biologist

Adrian Valente

PhD – Senior computational biologist

Corporate Board

ErVimmune Corporate

Stéphane Depil

MD, PhD – Founder, Chairman

Founder of the company. Onco-hematologist at Centre Léon Bérard and adjunct Professor at University Claude Bernard Lyon 1, former Visiting Professor at King’s College London. Over 15 years of experience in oncology research and drug development both in academia and pharma/biotech as former SVP R&D and CMO at Cellectis, CEO/CMO at Netris Pharma and Head of Oncology R&D at Servier.

Alain Herrera

MD – Member

Over 25 years of experience in the pharmaceutical industry with a strong focus on oncology drug development and marketing. Supervisory Board member of IDDI, Nanobiotix, PDC*line Pharma, Gustave Roussy-Transfert and Arcad Foundation. Former VP of Global Oncology BD at Sanofi, Chiron Therapeutics

Jérôme Martinez

Pharma D, MBA – Member
On the board of Theranexus SA, MDoloris Medical Systems SAS. Former President & CEO of BMI SYSTEM SAS, Senior VP BD for Ethypharm Corp., Chairman-Management Board & CEO at Novagali Pharma SA, Deputy Director at Alliance Santé SA and VP-Marketing & Business Development at Lavipharm Corp.

International Scientific Advisory Board (SAB)

led by Prof. Stéphane Depil

Prof. Jean-Yves Blay

Leon Bérard Cancer Centre – France
Professor Jean-Yves Blay is the Director of the Léon Bérard Cancer Centre since 2014 and President of Unicancer since 2019. He is an oncologist, researcher, and medical oncology professor at the Claude Bernard Lyon 1 University. Professor Blay is an active member of the ESMO, the American Society of Clinical Oncology and the American Association of Cancer Research. His research interests focus on clinical and basic research in sarcomas, targeted treatment of cancer, the biology of breast carcinoma and relation between tumor immunologic microenvironment and malignant cells with the goal of clinical applications in the fields of diagnosis, prognosis and treatment.

Prof. Pierre Coulie

de Duve Institute – UCLouvain – Belgium
Professor Pierre Coulie is leading a research group at the de Duve Institute and is an expert on the antigenicity and immunogenicity of human tumors. His current research deals with the immunogenicity of bladder carcinomas, particularly at the early stages of tumor development, with inflammatory cytokines production in the context of cancer and with the identification of antigens targeted by T cells in human autoimmune diseases.

Prof. Bernard Malissen

Centre d’Immunologie de Marseille-Luminy (CIML) – France
Professor Bernard Malissen directed the CIML from 1995 to 2005 where his team contributed to cracking the “TCR system”, the highly sophisticated molecular machinery that allows T cells to recognize the antigen and convert this information in a multitude of intracellular signals. He also studied one of the main partners of these cells, dendritic cells, which are responsible for presenting these antigens. Today, his research is focused on trying to address this complexity by combining “omics”, predictive models, patient biological samples with new computing power and digital analysis.

Prof. Stanley Riddell

Fred Hutchinson Cancer Research Center – US
Professor Stan Riddell is a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center and Professor of Oncology at the University of Washington School of Medicine. Professor Riddell is a world leader in developing immunotherapies, which harness the power of the immune system to fight cancers and dangerous infections. His research focuses on detailing the complex biology of immune cells called T cells and pioneering therapies that use genetically reprogrammed T cells to specifically recognize and destroy diseased cells. These therapeutic T cells target tumor antigens, using either natural molecules called T-cell receptors or synthetic molecules called chimeric antigen receptors. Chimeric antigen receptors, also known as CARs, combine elements from T-cell receptors and from other immune cell-produced antibody molecules. His team’s breakthroughs are helping researchers make progress for patients who need better therapies.

Dr Qing Wang

Complete Omics Inc. – US

Doctor Qing Wang graduated from Johns Hopkins University with a PhD, supervised by Dr. Bert Vogelstein at the School of Medicine, and an MHS in Biostatistics, supervised by Dr. Rafael Irizarry at the Bloomberg School of Public Health. Before coming to the US, he obtained his BS and MS in Molecular Biology from Nankai University and trained with Dr. Tianhui Zhu, the Founding Dean of Nankai University School of Medicine. Doctor Wang is also currently pursuing an Executive MBA from The Wharton School of the University of Pennsylvania and will obtain his degree in 2023. To date, Dr. Qing Wang has invented and patented 18 cutting-edge technologies in clinical multi-omics molecular diagnostic fields, ranging from early disease detection to companion diagnostics. Through Complete Omics Inc., Dr. Wang is working to break the boundaries between different fields in medicine and the life sciences and to comprehensively leverage the features of omics technologies to achieve improved personalized disease management and precision medicine.

About ErVimmune

Medical research and development, in particular the development of new families of tumour antigens.

Research, development and production of monoclonal antibodies and derivatives targeting new membrane antigens and any other activity of any nature whatsoever related to the biotechnology and/or pharmaceutical industry.

Useful links

> Publications & abstracts

> Recent news

> Legal notice


> Home

> About us

> Sciences

> Investors

> Join us

> Contact




+33 6 67 67 44 97

© 2023 ErVimmune | Next Generation Cancer Immunotherapies | Design by om&go